Exploring the infinite frontiers of an intelligent connected world

WUXI, China, Nov. 3, 2025 /PRNewswire/ — The World Internet of Things Exposition (WIoT) 2025, themed “Intelligent Connectivity, Infinite Frontiers”, took place in Wuxi from October 31 to November 2, 2025.

The opening ceremony featured the launch of two key Jiangsu provincial initiatives: the Key Laboratory of MEMS Sensor and ASIC Manufacturing Technology and the Industrial Internet Platform Enablement Center. At the same time, several important reports were released and project outcomes were announced, including the Top 10 IoT Trend Insights 2025 and the citywide pilot outcomes of the 5G-Advanced “Four-Integration” connected mobility initiative (integrating vehicles, roads, cloud, and network). Together, these efforts brought together global industry leaders and cutting-edge insights, setting the course for deeper IoT–AI integration and accelerating digital transformation across sectors.

A flagship awards program recognizing breakthrough IoT technologies, applications, and models drew strong participation from innovators and organizations across the IoT ecosystem. This year’s competition expanded to include both core tracks—Smart Sensors, Advanced Communications, Embodied Intelligence & Intelligent Connected Vehicles, and Industrial Internet—and emerging fields such as Satellite Internet and Quantum Sensing. From a pool of more than 800 global submissions, 50 projects were recognized, including 10 Gold Award winners announced during the ceremony.

WIoT 2025 brought together an outstanding lineup of experts and business leaders renowned for their forward-looking research and practical exploration in the IoT field, who delivered keynote sessions on key topics such as AI, satellite IoT, and brain-computer interfaces. Among the speakers was Zhang Yaqin, Foreign Member of the Chinese Academy of Engineering and Dean of the Institute for AI Industry Research (AIR) at Tsinghua University.

Building on its established market-oriented organizing approach, WIoT 2025 continued to emphasize collaboration and innovation at the intersection of AI and IoT. The Expo highlighted a global perspective, professional expertise, executive-level dialogue, and real-world industry application. Through a comprehensive program featuring an opening ceremony, seven themed forums, an industry exhibition, a flagship awards competition, and 16 ecosystem events, it brought together international expertise and industry resources to accelerate innovation and sustainable growth across the IoT sector.

• Wegovy^® (semaglutide) is a once-weekly injectable prescription medicine used in combination with a reduced calorie diet and increased physical activity for adults and adolescents aged 12 years old or above with obesity or adults with overweight in the presence of at least one related health condition.
• In Hong Kong, with over 30% of adults classified as obese^[1] and 20% of adolescents being overweight or obese^[2], Wegovy^® offers an effective treatment option to help combat the rising health burden.
• The launch of Wegovy^® in Hong Kong extends Novo Nordisk’s commitment to addressing obesity as a chronic disease through clinically proven treatments.

HONG KONG, Nov. 3, 2025 /PRNewswire/ — Leading global healthcare company Novo Nordisk announces the launch of Wegovy^® in Hong Kong, now available at private clinics and selected pharmacies. Clinically proven for long-term weight management, Wegovy^® represents a significant step forward in addressing the city’s escalating health burden through evidence-based care for obesity as a chronic disease.

Wegovy^® is a once-weekly injectable prescription medication used as an adjunct to a reduced calorie diet and increased physical activity for effective long-term weight management. Wegovy^® is indicated for^[3]: 

• Adults with BMI ≥30 kg/m², or
• Adults with BMI ≥27 to <30 kg/m² and have at least one weight-related medical condition, such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease, or
• Adolescents aged 12 years and above with obesity (BMI ≥95th percentile, as defined on sex- and age-specific BMI growth charts [CDC.gov]) and a body weight above 60 kg

Wegovy^® is the first once-weekly prescription weight-loss medication approved for adolescents aged 12 and above in Hong Kong.

Wegovy^® contains semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist that helps regulate appetite. By modulating brain’s central hub for hunger and satiety control, Wegovy^® helps patients lower their energy intake, enhances feelings of fullness and control over-eating, and experience fewer and less intense cravings.

As the world’s first once-weekly GLP-1 receptor agonist formulation for long-term weight management, global large-scale clinical studies – the STEP program and the SELECT study have demonstrated Wegovy^®‘s efficacy in achieving sustained weight loss and improving obesity-related health outcomes. In a 68-week STEP 1 clinical trial, about one-third of adults treated with Wegovy^® achieved an average weight reduction of 20% or more, compared to just 2% in a placebo group^[4]; the average weight loss achieved in the STEP trials is up to 17%^[5]. At the same time, Wegovy^®‘s safety has been extensively examined with its active ingredient semaglutide accumulating 33 million patient years of exposure^[6]. These findings reinforce Wegovy^® as an evidence-based treatment option for long-term obesity care under medical supervision.

Obesity is a complex chronic disease and an increasingly urgent health challenge in Hong Kong. According to the Hong Kong 2020-2022 Population Health Survey, 32.6% of adults aged 15 to 84 are classified as obese (BMI ≥ 25 kg/m²), and 22.0% as overweight (BMI 23-25 kg/m²)^[1]. Student Health Service Annual Health Report for 2023/24 School Year from the Department of Health indicates that 20% of secondary school students are classified as overweight or obese^[2]. Despite its high prevalence, public awareness remains low: a recent study found that over one-third of obese respondents considered themselves only “slightly overweight”, while 70% were unaware that obesity is defined by the World Health Organization as a chronic disease^[7],[8].

Being overweight or obese is associated with more than 200 diseases, including cardiovascular disease, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnoea, certain cancers, and metabolic dysfunction-associated steatotic liver disease (MASLD)^[9]. Among these, cardiovascular disease is the leading cause of death in patients with obese^[10]. Without effective intervention, the global economic burden of obesity and overweight is projected to exceed US$3 trillion annually by 2030 and US$18 trillion by 2060^[11]. These findings underscore the urgent need for long-term, evidence-based solutions to support healthier outcomes across all age groups.

Mr Anirvan Dutt-Chaudhuri, General Manager, Novo Nordisk Hong Kong, said: ” Wegovy^® ‘s benefits have been extensively demonstrated in individuals who are caring about obesity or overweight, with robust evidence supporting its impact on improving health outcomes. Its launch in Hong Kong marks a pivotal moment in recognizing obesity as a chronic medical condition that requires sustained, science-based care. As a global leader in obesity treatment for over 25 years, Novo Nordisk is proud to expand access to innovative therapies and offer healthcare professionals and patients more evidence-based options through a comprehensive, patient-centric approach to weight management.”

In Hong Kong, Novo Nordisk has been actively partnering with medical groups and professional associations to strengthen clinical collaboration and support long-term care initiatives. Over the years, the company has also led public awareness campaigns to emphasize the importance of addressing obesity. With the launch of Wegovy^®, Novo Nordisk reinforces its commitment to patients with weight management issues.

More photos can be downloaded from this link.

About Wegovy

Wegovy^® is a once-weekly injectable prescription medication used as an adjunct to a reduced calorie diet and increased physical activity for effective long-term weight management. Wegovy^® is indicated for:

• Adults with BMI ≥30 kg/m², or
• Adults with BMI ≥27 to <30 kg/m² and have at least one weight-related medical condition, such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease, or
• Adolescents aged 12 years and above with obesity (BMI ≥95th percentile, as defined on sex- and age-specific BMI growth charts [CDC.gov]) and a body weight above 60 kg

About the STEP clinical program

STEP (Semaglutide Treatment Effect in People with obesity) is a global clinical phase 3 program consists of multiple trials enrolling adults with overweight or obesity. STEP 1 is 68-week, randomized, double-blind, multicentre, placebo-controlled phase 3 clinical trial with semaglutide in obesity. The results revealed that semaglutide 2.4 mg shows superior weight loss compared to placebo in the trials.

About SELECT clinical study

SELECT (Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity) is a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of semaglutide 2.4 mg versus placebo as an adjunct to standard of care for the prevention of major adverse cardiac events (MACE) in people with overweight or obesity and established cardiovascular disease with no prior history of diabetes. Results demonstrated that semaglutide significantly lower the risk of MACE such as death, heart attack, or stroke compared to placebo in the trial.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries.

For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

References

1.  Centre for Health Protection, Hong Kong. Obesity. 26 April 2023. https://www.chp.gov.hk/en/healthtopics/content/25/8802.html. As accessed on 21 August 2025.

2.  Department of Health, Hong Kong. Student Health Service Annual Health Report for 2023/24 School Year. April 2025.
https://www.studenthealth.gov.hk/english/annual_health/files/student_health_service_annual_health_report_for_2023_24_school_year.pdf. As accessed on 25 September 2025.

3.  Novo Nordisk. Wegovy^® Hong Kong Prescribing Information. June 2025

4.  Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.

5.  Bergmann NC, et al. Semaglutide for the treatment of overweight and obesity: A review. Diabetes Obes Metab. 2022 Oct 18;25(1):18-35.

6.  Novo Nordisk – a focused healthcare company. Investor presentation: First three months of 2025. https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2025/Q1-2025-investor-presentation.pdf. As accessed on 29 September 2025.

7.  Singtao Headline. News. 27 August 2025. https://www.stheadline.com/society/3493944/. As accessed on 29 August 2025.

8.  World Health Organization. 2000. Obesity: Preventing and managing the global epidemic (WHO Technical Report Series No. 894). https://apps.who.int/iris/handle/10665/42330. As accessed on 25 September 2025.

9.  De Lorenzo A, et al. Why primary obesity is a disease? J Transl Med. 2019 May 22;17:169. 

10.  Afshin A, et al.  Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017 Jul 6;377(1):13-27.

11.  World Health Organization. Obesity and overweight. 7 May 2025. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. As accessed on 21 August 2025. 

Disclaimer

This press release is intended for the purpose of providing updated scientific and market information. This press release does not constitute a recommendation, promotion, or advertisement for any drug or treatment regimen. Readers should not make any decisions regarding the purchase or use of any drug or treatment regimen based on, by reference to, or in reliance upon any content herein. For any questions regarding drugs or treatments, readers should consult healthcare professionals.

Before forwarding, using, or otherwise processing the information contained in this press release, relevant parties shall be responsible for ensuring their actions comply with all applicable laws, regulations, and regulatory requirements of any relevant country or jurisdiction. Any direct or indirect consequences arising from the citation, reproduction, editing, or other use of the information contained in this press release shall be the sole responsibility of the relevant parties, and Novo Nordisk shall not be liable for any such consequences. It is recommended that relevant parties carefully assess risks before forwarding, using, or otherwise processing the information contained in this press release, and seek professional legal advice when necessary.

GYEONGJU, South Korea, Nov. 3, 2025 /PRNewswire/ — On November 3, 2025, Hong Kong-listed company Star Plus Legend Holdings Limited (Stock Code: 06683.HK) issued an announcement stating that it has completed a strategic investment in Galaxy, a well-known South Korean artist management company, through an industrial fund. The company subscribed for no more than 7% of Galaxy’s issued share capital, with an initial delivery contribution of USD 8 million, accounting for 16% of the fund’s equity. Galaxy represents internationally influential artists such as G-Dragon, Kim Jong-kook, and Song Kang-ho, and this cooperation is regarded by the market as a crucial step for Star Plus Legend Holdings Limited to accelerate its global IP layout.

Prior to this, G-Dragon, an iconic figure in the K-pop industry, made an appearance at the APEC Gyeongju Evening Gala, demonstrating his influence on the international stage. Star Plus Legend Holdings Limited’s investment in Galaxy will further strengthen its ties to such high-quality artist resources, endowing the investment with greater market imagination and laying the foundation for cooperation between the two parties in areas including global concert tours, large-scale theme exhibitions, and the development of artist IP and derivatives.

In recent years, Star Plus Legend Holdings Limited has centered its operations on super IPs such as “CHOUCHOU” and “Coach Liu”. It has accumulated 280 million fans and generated over RMB 1 billion in sales from authorized co-branded products, demonstrating strong IP operation capabilities. Artists under Galaxy have achieved outstanding results in music, variety shows, and film. G-Dragon’s influence in fashion and music, Kim Jong-kook’s national popularity in variety shows, and Song Kang-ho’s status in the international film industry will provide support for Star Plus Legend Holdings Limited to expand into Asian and even global markets.

Driven by this news, Star Plus Legend Holdings Limited’s stock price opened higher and moved upward on the day, with an intraday increase of more than 10% at one point, reflecting the market’s recognition of its strategic layout. Industry analysts believe that this investment will not only help Star Plus Legend Holdings Limited expand from the Chinese-speaking market to the global market but also realize the mutual empowerment of brand influence between the two parties, unlocking more possibilities for the “IP+” model.

Star Plus Legend Holdings Limited stated that it will conduct in-depth discussions with Galaxy on specific cooperation details, leverage its advantages in IP creation and full-link operation, promote the global market implementation of cooperative projects, and build a global ecosystem of “IP + Products + Technology + Channels”. This series of actions conveys the company’s determination to actively expand into the international market and strengthen the integration of top-tier IP resources, which is expected to bring long-term value growth to shareholders.

HONG KONG, Nov. 3, 2025 /PRNewswire/ — On November 3, 2025, Ant Digital Technologies (Ant DT) unveiled its full‑scenario AI solutions to the global market at Hong Kong FinTech Week. Showcased solutions — including large‑model agent platform Agentar, AI security and risk platform ZOLOZ, and AI‑driven mobile banking solutions, etc.

Ant DT’s full‑scenario AI offering integrates end‑to‑end capabilities — large‑model agents, knowledge engineering, data governance and full‑stack risk control — to help financial institutions and enterprises worldwide accelerate growth, innovate customer experiences and strengthen risk posture in the AI era.

On risk management, the rise of generative AI has introduced new threats such as Deepfake attacks. To combat the growing global challenge of deepfakes, ZOLOZ delivers millisecond-level fraud detection and protection, ensuring robust security for enterprise customers and assets. Its eKYC solution is already serving several local partners in Hong Kong.

In terms of business growth, Ant DT’s AI marketing agent performs intelligent data analysis and generates personalized marketing strategies aligned with business goals. In one bank deployment, this approach improved marketing effectiveness by around 20% compared with traditional campaigns.

On customer experience, the company’s AI mobile banking introduces a “conversation‑as‑a‑service” model: customers use natural language to request services, and the AI assistant responds in real time and completes transactions such as transfers, repayments, and pension inquiries. Early results at Bank of Shanghai show a 10% lift in mobile‑banking conversion rates and a marked increase in user satisfaction.

According to data disclosed by the Hong Kong Monetary Authority (HKMA), over 75% of banks in Hong Kong have incorporated AI into their operations by 2025. AntDT is also sharing its proven AI innovations with partners around the world. In October, it was selected to join the HKMA’s Generative AI Sandbox as technology partner. In July, Ant DT aslo forged a strategic partnership with The Hong Kong Polytechnic University (PolyU) to jointly establish an AI and Web3 Lab. To date, Ant Digital Technologies has served over 100 financial institutions in Hong Kong and abroad.

VENICE, Italy, Nov. 3, 2025 /PRNewswire/ — The 19th Venice Architecture Biennale, held from May 10 to November 23, 2025, showcases the fusion of art and technology through the collaboration between Huawei and the China Pavilion. As the Chief Intelligence and Technology Partner for the China Pavilion, Huawei has integrated its innovative products—including the HUAWEI Mate X6, HUAWEI MatePad Pro 12.2-inch PaperMatte Edition, and HUAWEI MatePad Pro 13.2-inch PaperMatte Edition—into the pavilion’s design, highlighting China’s architectural heritage with smart technologies.

To further celebrate this technological partnership, the HUAWEI WATCH GT 6 Series, launched in September 2025, introduces three exclusive watch faces inspired by the installation works featured at the Biennale. These watch faces inject the essence of architectural and artistic aesthetics into everyday life, offering users a unique way to experience the fusion of art and technology.

The Dunhuang Con-stella-tion watch face is inspired by the installation work “Dunhuang Con-stella-tion” by Atelier Alter Architects. This piece reflects the historical significance of Dunhuang as a crossroads of civilizations along the Silk Road, where diverse cultures intersected to create new kinds of art. This is particularly evident in the four domes of Mogao Cave 285, where architectural elements from Greece, Persia, India, and China converge, symbolizing how diverse civilizations imagine the cosmos. In the “Dunhuang Con-stella-tion” installation, the architect envisions Dunhuang as a futuristic floating city, epitomizing the harmonious blend of diverse cultures and the ethereal beauty of nebulae, in modern ode to the concept of “civilization resonance.”

The Vault of Heaven watch face is inspired by the installation work “Vault of Heaven” by Wang Zigeng, associate professor of the Department of Architecture of the Central Academy of Fine Arts and founder and principal architect of PILLS. The artwork reimagines the traditional “caisson ceiling” architectural element using recycled green protective nets from Chinese construction sites. The dynamic design incorporates bamboo weaving, an intangible cultural heritage, and creates a mesmerizing visual effect reminiscent of a phenakistoscope. This not only pays homage to the ancient “caisson ceiling” as a representation of the “heavenly palace” in temple architecture, but also weaves a continuous narrative of interconnected moments. These fleeting yet profound instants revolve around China’s unique natural philosophy, vividly showcasing the poetic imagination of heaven and the never-ending pursuit of a better life by the Chinese people.

The City in China – Nature of All Things watch face is inspired by the “City in China – Nature of All Things” installation by WAY studio, envisioning a future city where natural surroundings seamlessly integrate with urban architecture. This innovative design reimagines the connection between skyscrapers through an advanced transportation system, significantly reducing energy consumption. The artwork also emphasizes the concept of organic growth in buildings, much like living organisms.

Huawei uses these watch faces as a medium to seamlessly integrate the “CO-EXIST” theme of the China Pavilion into its cutting-edge tech products, bridging the gap between art, architecture, and wearable technology. This innovative approach pushes the boundaries of cultural expression further. Users of the HUAWEI WATCH GT 6 Series can now experience these unique watch faces, blending Eastern aesthetics with smart living in a way that is both elegant and functional.

Huawei has consistently embraced an open, diverse, and international perspective, drawing inspiration from global artistic movements and continuously exploring the infinite possibilities of design. Huawei remains dedicated to pioneering advancements in technological aesthetics, aiming to deliver premium and stylish tech experiences to global consumers, and empowering them to embrace a more personalized lifestyle.

SINGAPORE, Nov. 3, 2025 /PRNewswire/ — Huawei is proud to join the 25th Conference of Electric Power Supply Industry (CEPSI 2025) as gold sponsor, hosted by the president of Association of the Electricity Supply Industry of East Asia and the Western Pacific (AESIEAP), SP Group, under the theme “Empowering the Energy Transition“. By collaborating with industry partners and embracing the energy ecosystem, Huawei engaged over 4000 energy leaders, government representatives, and customers. During the event, Huawei unveiled new features of its Intelligent Substation Solution, fostering dialogue with energy experts from East Asia and the Western Pacific on energy transition, smart grids, and future power innovation.

Jason Li, President of Huawei Global MKT & Solution, Electric Power Digitalization Business Unit, stated that “The portfolio of automation, and digitalization and AI will become the key drivers for grid modernization. We believe that the deep integration of digital technologies into electric power scenarios, and the reconstruction of production and operation modes through communication and AI technologies can help meet dual- requirements of ultimate stability and ultimate flexibility.” This model is showcased in Huawei Intelligent Substation’s new intelligent perimeter fiber sensing features.

Traditional substations often rely heavily on manual operations, and passive monitoring systems that fail to detect complex risks. Equipment status checks remain fragmented, with inefficient manual inspections leading to missed defects and operational vulnerabilities. Huawei’s solution leverages fiber optics and a sensing algorithm engine to detect vibration waveform changes, combined with Huawei AI large-model algorithms to accurately identify personnel or foreign object intrusions. Using the management system to coordinate perimeter sensing terminals, on-site verification is performed for secondary confirmation by operations staff. This fiber-visual integration approach achieves extremely low false alarm and missed detection rates.

Leo Zhang, Vice President of Huawei Enterprise Optical Network Domain, highlighted in his speech, “The AI-based intelligent fiber-optic sensing solution enhances perimeter protection and underground cable security for substations and power plants through high precision, environmental resilience, and 24/7 monitoring. This has significantly improved the safety while reducing manual inspection costs and boosting operational efficiency.”

Jacky Wang, Vice President of Electric Power Digitalization Business Unit, addressed that “For the energy industry, real-time and high-quality data are essential to get the most out of AI, while highly reliable communication networks are the foundation for real-time, high-quality data. We need to redefine digital scenarios and the communication target network, as well as reposition network security.” He also noted, “Computing power is the foundation of AI, electricity is the ceiling of computing power and AI is the future of electricity.”

Jing Kong, CMO of Beijing Yueneng Technology Co, Ltd., shared her thought, “AI+ will help new energy grow healthier and smarter—turning that “grow well, not just fast. It will help build a greener planet for all of us. Yueneng partners with Huawei to drive the digital transformation of new energy together!”

During the event, Huawei hosted the IDS Club roundtable and the APAC Energy Power Partner Forum, engaging both customers and partners on regional development and opportunities. Energy companies also visited Huawei OpenLab to explore its intelligent power solutions. In short, Huawei will continue working with customers and partners to accelerate the energy industry’s digital and intelligent transformation.

Learn more about Huawei’s Intelligent Substation Solution: https://e.huawei.com/en/industries/grid/power-grid/smart-substation